2 weeks Ago By ABMN Staff
Corebridge Financial Inc. cut its holdings in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Free Report ) by 7.
0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 28,098 shares of the biopharmaceutical company’s stock after selling 2,122 shares during the period.
Corebridge Financial Inc.’s holdings in Agios Pharmaceuticals were worth $923,000 at the end of the most recent reporting period. Other large investors also recently added to or reduced their stakes in the company.
State Street Corp raised its position in Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the period.
Frazier Life Sciences Management L.P. raised its holdings in shares of Agios Pharmaceuticals by 19.
7% in the third quarter. Frazier Life Sciences Management L.P.
now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after buying an additional 172,180 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Agios Pharmaceuticals by 12.3% during the 4th quarter.
Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company’s stock worth $31,567,000 after acquiring an additional 105,333 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Agios Pharmaceuticals by 464.
3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,678 shares of the biopharmaceutical company’s stock valued at $4,130,000 after acquiring an additional 103,405 shares during the period.
Finally, Bank of New York Mellon Corp grew its position in Agios Pharmaceuticals by 48.8% in the 4th quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company’s stock valued at $8,725,000 after acquiring an additional 87,089 shares during the last quarter.
Agios Pharmaceuticals Price Performance Shares of AGIO opened at $25.76 on Friday. The firm has a market capitalization of $1.
48 billion, a PE ratio of 2.27 and a beta of 0.90.
The company’s fifty day moving average price is $32.55 and its 200-day moving average price is $40.23.
Agios Pharmaceuticals, Inc. has a 1-year low of $25.26 and a 1-year high of $62.
58. Insider Buying and Selling In related news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.
18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.
08. The trade was a 12.92 % decrease in their position.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . 4.93% of the stock is currently owned by insiders.
Analysts Set New Price Targets Several analysts have recently weighed in on the company. HC Wainwright began coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.
00 target price for the company. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th.
Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.
00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Finally, Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.
00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $56.
57. View Our Latest Analysis on AGIO Agios Pharmaceuticals Company Profile ( Free Report ) Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Free Report ).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
